A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
Top Cited Papers
Open Access
- 1 April 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (7) , 2080-2087
- https://doi.org/10.1158/1078-0432.ccr-05-1263
Abstract
Purpose: In the adjuvant treatment of estrogen receptor (ER)–positive breast cancer, additional markers are needed to identify women at high risk for recurrence.Keywords
This publication has 33 references indexed in Scilit:
- Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment OutcomeJNCI Journal of the National Cancer Institute, 2005
- Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic TherapyClinical Cancer Research, 2005
- Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotypeAnnals of Oncology, 2005
- Expression of interleukin-17B in mouse embryonic limb buds and regulation by BMP-7 and bFGFBiochemical and Biophysical Research Communications, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994
- Why do so many prognostic factors fail to pan out?Breast Cancer Research and Treatment, 1992